Direct oral anticoagulant monotherapy vs combination therapy with antiplatelets in chronic coronary syndrome patients with prior percutaneous coronary intervention requiring anticoagulation: A meta-analysis.
Kuan-Yu Chi, Aditya Karthikeyan, Yu Chang et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis of randomized trials evaluated the effects of direct oral anticoagulant (DOAC) monotherapy versus combination therapy with antiplatelets in chronic coronary syndrome patients post-percutaneous coronary intervention. The study found that DOAC monotherapy significantly reduced major adverse cardiac and cerebrovascular events and major bleeding without increasing ischemic events, highlighting its potential benefits in this high-risk population.
Key findings
- DOAC monotherapy significantly reduced major adverse cardiac and cerebrovascular events.
- There was a notable reduction in all-cause and cardiovascular mortality with DOAC monotherapy.
- Major bleeding was reduced without an increase in ischemic events.
Why it matters
Understanding the comparative effectiveness of anticoagulation strategies is crucial for managing patients with chronic coronary syndrome, particularly those at high risk for bleeding and cardiovascular events. This evidence supports a potential shift towards DOAC monotherapy in appropriate patients.